TAG

regulatory

10 articles tagged regulatory.

BPC-157 Research Status in 2026: What Clinicians and Regulators Currently Say

BPC-157 is not FDA-approved. Here is what the 2026 Category 2 list change, the PCAC vote, and current clinical literature actually mean for patients.

October 3, 2026

glp-1

Compounded Tirzepatide Shortage Rules in 2026: What Changed and What Stayed the Same

FDA removed tirzepatide from its shortage list in late 2024. Here is what that meant for compounded tirzepatide access heading into 2026, and what did not change.

September 30, 2026

trt

Compounded Testosterone vs. Commercial Formulations: What the Regulatory Pathway Actually Means

Compounded testosterone and commercial testosterone travel different regulatory paths. Here is what FDA oversight, 503A rules, and quality checks actually mean for TRT patients.

September 29, 2026

peptides

503A vs. 503B Pharmacies: Why the Compounding Pathway Determines Peptide Access

503A and 503B pharmacies follow different FDA rules, and that difference decides which peptides a clinician can legally prescribe. Here's what it means for patients.

September 26, 2026

peptides

PT-141: What the Research Says About Its Current FDA Regulatory Status

Is PT-141 FDA-approved? Learn how Vyleesi's 2019 approval differs from compounded PT-141, what the research shows, and how prescribing actually works.

September 26, 2026

glp-1

What Does "Compounded" Mean for GLP-1 Medications? A Plain-Language Guide

A plain-language breakdown of what compounded means for GLP-1 medications, how it differs from FDA-approved brand drugs, and the pharmacy pathway behind it.

September 15, 2026

glp-1

Compounded GLP-1s After the Shortage: What Current 503A Rules Mean for Access

The national GLP-1 shortage has ended. Here's what FDA's 503A rules actually allow now, who still qualifies for compounded access, and how to check your options.

August 4, 2026

glp-1

Compounded Semaglutide vs. Ozempic: What "Compounded" Actually Means

Compounded semaglutide is not Ozempic. Here's what compounding actually means, how it differs from FDA regulatory review, and what to ask before starting.

August 2, 2026

peptides

GHK-Cu Peptide: Topical vs. Injectable, and What the Research Actually Shows

GHK-Cu is best known as a cosmetic copper peptide. Here's what separates topical use from investigational injectable use, and why the distinction matters.

August 2, 2026

peptides

BPC-157: What the Peptide Is, Safety Signals, and Current Regulatory Status

BPC-157 explained: what the peptide is, what preclinical and early human data show, and why its FDA regulatory status limits compliant compounding today.

August 2, 2026